Kane Biotech Inc. V.KNE

Alternate Symbol(s): KNBIF

Healthcare Biotechnology

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.

TSXV:KNE - Post by User

Kane Biotech Inc.

<< Previous

Bullboard Posts

Next >>

Post by StoneMan45on Sep 30, 2021 8:03am

167 Views

Post# 33942398

STEM

Snippets related to STEM from AnimalCares Group’s recent release.

28 September 2021. Animalcare Group plc ("the Company" or "Group") (AIM: ANCR), the international animal health business, announces its unaudited interim results for the six months ended 30 June 2021.

Revenue increased 13.3% (14.2% at CER) to £39.1m compared to prior period (H1 2020: £34.5m) with sales growth particularly strong within Companion Animals

Strategic and Operational Highlights

Pipeline

Following approval by EU and UK authorities, Daxocox launch activities commenced at the end of the first half while the STEM dental range of products remains on track to complete manufacturing transfer and launch in late Q4
The Group plans to increase investment in the development pipeline versus the prior year and further still into 2022

3. Building our pipeline

......................

For the STEM joint venture with Kane Biotech, biofilm pipeline projects have commenced, with a particular focus on otitis. To support delivery of pipeline opportunities, total R&D investment is expected to increase versus the prior year and further still into 2022.

With the completion of manufacturing transfer, we also expect to add biofilm treatments from our STEM joint venture to our line-up of new products in the fourth quarter.

Companion Animals, which represents the majority of our business at around 70% of Group turnover, grew at 29.1% over the corresponding period last year. This growth can be attributed to strong market dynamics, particularly in Southern Europe where overall trading additionally benefited from the effects of phasing, newly introduced products and favourable comparisons to the prior period when the effects of COVID-19 were prevalent across the animal health industry.

We are allocating resources to growth opportunities including new products such as Daxocox - which is early in its launch phase - and the STEM biofilm range of treatments for which we expect to complete manufacturing transfer ahead of introduction to our markets in the fourth quarter.